# US 2021/0330810 A1 · Compositions containing nucleic acid nanoparticles with modular functionality

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330810 A1
- Document ID: US20210330810A1
- Status: Published application
- Kind: A1
- Application number: 17/241,920
- Filed: 2021-04-27
- Published: 2021-10-28
- Earliest claimed: 2020-04-27
- Assignees: Sixfold Bioscience Ltd.
- Applicants: Sixfold Bioscience Ltd.
- Inventors: James Luke Rushworth; George William Foot; Anna Perdrix Rosell; Zuzanna Aleksandra Brzosko
- Web page: https://patentgrep.com/patent/US20210330810A1

## CPC

- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/16: Aptamers
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3513: Protein; Peptide
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3519: Fusion with another nucleic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule.

## Claims

### Claim 1

A composition comprising:
an oligonucleotide covalently linked to one or more cargo molecules.

### Claim 2 (depends on 1)

The composition of claim 1, whereby the oligonucleotides are:
functionalized with reactive sites that allow for conjugation; and
conjugated to a nucleic acid nanoparticle.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the nucleic acid nanoparticle is a tertiary structure of three or more junctions, said junctions are formed by at least two oligonucleotide strands of 3 to 200 nucleotides in length, wherein each oligonucleotide strand partially interacts with at least one other oligonucleotide strand through either hydrogen bonding or base-stacking interactions or both.

### Claim 4 (depends on 3)

The composition of claim 3, wherein each nucleotide optionally comprises a modification including, but not limited to, 2′-O-methyl, 2′-fluoro, 2′-F-arabinonucleic acid, 2′-O-methoxyethyl, locked nucleic acid, unlocked nucleic acid, 4′-thioribonucleoside, 4′-C-aminomethyl-2′-O-methyl, cyclohexenyl nucleic acid, hexitol nucleic acid, glycol nucleic acid, phosphorothioate, boranophosphate, 5′-C-methyl, 5′(E)-vinylphosphonate, and 2′ thiouridine.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the nucleic acid nanoparticle is attached to a cargo molecule, wherein the cargo molecule promotes a biological activity of the cargo molecule in a subject.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the nucleic acid nanoparticle performs at least one biological activity selected from the group:
(i) binding to a serum protein in blood, or to a receptor in a cell or at the cell surface;
(ii) promoting endosomal escape of the cargo molecule in a receptor-independent manner;
(iii) targeting a tissue in an animal or subject;
(iv) modulating biodistribution;
(v) inducing or preventing an immunological response;
(vi) enhancing cellular uptake;
(vii) modulating gene expression;
(viii) inducing cytotoxicity; and
(ix) having a therapeutic effect;
or combinations thereof.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the one or more cargo molecules are comprised of at least one of mRNA, gRNA/CRISPR, siRNA, shRNA, ASO, saRNA, miRNA, InRNA, ribozyme, aptamer, peptide, protein, protein domain, antibody, antibody fragment, antibody mimetic, lectin, vitamin, lipid, carbohydrate, benzamides and therapeutic small molecules, or combinations thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the functionalization promotes internalisation into the cell, wherein the internalisation mechanism comprises at least one of clathrin-mediated endocytosis, non-clathrin/non-caveolae endocytosis, caveolae-mediated endocytosis, passive diffusion, simple diffusion, facilitated diffusion, transcytosis, macropinocytosis, phagocytosis, receptor mediated endocytosis, receptor diffusion, vesicle-mediated transport, and active transport.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the attachment of the nucleic acid nanoparticle to at least one cargo molecule is obtainable by a method comprising at least one reaction that comprises at least one of the following features:
(i) the reaction occurs in one pot;
(ii) the reaction is not disturbed by water;
(iii) the reaction generates minimal byproducts; and
(iv) the reaction comprises a high thermodynamic driving force that affords a single reaction product.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the attachment reaction comprises:
(i) attaching a first cargo molecule via a first reaction comprising at least one of the features of claim 9; and
(ii) attaching a second cargo molecule via a second reaction comprising at least one of the features of claim 9;
wherein the first reaction and the second reaction are orthogonal.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the oligonucleotide 5′, 3′ or internal position (at any given position on a nucleotide) is modified with a functionality that will allow for the formation of covalent bonds via reactions selected from the group consisting of CuAAC, SPAAC, RuAAC, IEDDA, SuFEx, SPANC, hydrazone/oxime ether formation, thiol-ene radical reaction, thiol-yne radical reaction, thiol-Michael addition reaction, thiol-isocyanate reaction, thiol-epoxide click reaction, nucleophilic ring opening reactions (spring-loaded reactions), traceless Staudinger ligation. These linkages may be formed by carrying out coupling reactions with any oligonucleotide or cargo molecule modified with a chemical moiety from the group consisting of, but not limited to, ADIBO-PEG4, N-[(1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl]-1,8-diamino-3,6-dioxaoctane, (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol, bromoacetamido-dPEG®4-amido-DBCO, bromoacetamido-dPEG®12-amido-DBCO, bromoacetamido-dPEG®24-amido-DBCO, dibenzocyclooctyne-acid, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-PEG4-acid, dibenzocyclooctyne-PEG4-alcohol, dibenzocyclooctyne-PEG4-N-hydroxysuccinimidyl ester, (4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, (E)-cyclooct-4-enol, (E)-cyclooct-4-enyl 2,5-dioxo-1-pyrrolidinyl carbonate, 2,5-Dioxo-1-pyrrolidinyl 5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate, 5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoic acid, 5-norbornene-2-acetic acid succinimidyl ester, 5-norbornene-2-endo-acetic acid, methyltetrazine-NHS ester, methyltetrazine-PEG4-NHS ester, TCO PEG4 succinimidyl ester, TCO-amine, tetrazine-PEG5-NHS ester, alkyne-PEG5-acid, (R)-3-amino-5-hexynoic acid hydrochloride, (S)-3-amino-5-hexynoic acid hydrochloride, (S)-3-(boc-amino)-5-hexynoic acid, N-boc-4-pentyne-1-amine, boc-propargyl-Gly-OH, 3-ethynylaniline, 4-ethynylaniline, propargylamine hydrochloride, propargyl chloroformate, propargyl-N-hydroxysuccinimidyl ester, propargyl-PEG2-acid, 3-(4-azidophenyl)propionic acid, 3-azido-1-propanamine, 3-azido-1-propanol, 4-carboxybenzenesulfonazide, O-(2-aminoethyl)-O′-(2-azidoethyl)heptaethylene glycol, O-(2-aminoethyl)-O′-(2-azidoethyl)nonaethylene glycol, O-(2-aminoethyl)-O′-(2-azidoethyl)pentaethylene glycol, azido-dPEG®4(n)acid (where n could be 4, 8, 12, 24), azido-dPEG®(n)-amine (where n could be 7, 11, 23, 35), azido-dPEG®4(n) NHS ester (where n could be 4, 8, 12, 24), azido-dPEG®(n)-TFP ester (where n could be 4, 8, 12, 24, 36), 2-[2-(2-azidoethoxy)ethoxy]ethanol, O-(2-azidoethyl)-O-[2-(diglycolyl-amino)ethyl]heptaethylene glycol, O-(2-azidoethyl)heptaethylene glycol, O-(2-azidoethyl)-O′-methyl-triethylene glycol, O-(2-azidoethyl)-O′-methyl-undecaethylene glycol, 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-amine, 14-azido-3,6,9,12-tetraoxatetradecanoic acid, 11-azido-3,6,9-trioxaundecan-1-amine, bromoacetamido-dPEG®(n)azide (where n could be 3, 11, 23) and combinations thereof.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the nucleic acid nanoparticle is attached to:
a first cargo molecule; and
a second cargo molecule linked to the first cargo molecule; and
optionally, further cargo molecules linked to the second or first cargo molecule.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the first cargo molecule is selected from the group consisting of at least one of mRNA, gRNA/CRISPR, siRNA, shRNA, ASO, saRNA, miRNA, InRNA, ribozyme, aptamer, peptide, protein, protein domain, antibody, antibody fragment, antibody mimetic, lectin, vitamin, lipid, carbohydrate, benzamides and therapeutic small molecules, or combinations thereof.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the first cargo molecule is linked to the second cargo molecule by a cleavable linker.

### Claim 15 (depends on 14)

The composition of claim 14, wherein at least one of the first and second cargo molecules is linked to a third cargo molecule by either a thiol-cleavable linker comprising dithiobismaleimidoethane and 1,4-bis[3-(2-pyridyldithio)propionamido]butane, a hydroxylamine-cleavable linker comprising ethylene glycol bis(succinimidyl) succinate, a base-cleavable linker comprising bis[2-(N-succinimidyl-oxycarbonyloxy)ethyl] sulfone or a Meldrum's acid derivative comprising 5-(bis(methylthio)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione.

### Claim 16 (depends on 12)

The composition of claim 12, wherein at least one of the first and second cargo molecules is linked to a third cargo molecule by a dicer substrate or extended nucleic acid spacer region that is amenable to cleavage, including, but not limited to, the sequences (T)k, (A)l, (G)m, (C)n, and combinations thereof, where k, 1 m, and n are positive integers.

### Claim 17 (depends on 12)

The composition of claim 12, wherein at least one of the first and second cargo molecules is linked to a third cargo molecule with a linker selected from the group consisting of 1,8-bismaleimido-diethyleneglycol, 1,11-bismaleimido-triethyleneglycol, 1,4-bismaleimidobutane, bismaleimidohexane, bismaleimidoethane, tris(2-maleimidoethyl)amine), N-α-maleimidoacet-oxysuccinimide ester, N-β-maleimidopropyl-oxysuccinimide ester, N-ε-maleimidocaproic acid, N-γ-maleimidobutyryl-oxysuccinimide ester, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate), succinimidyl 6-(3(2-pyridyldithio)propionamido)hexanoate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, succinimidyl iodoacetate, succinimidyl (4-iodoacetyl)aminobenzoate, PEGylated, long-chain SMCC crosslinkers, succinimidyl 4-(p-maleimidophenyl)butyrate and sulfo-NHS equivalents), and p-maleimidophenyl isocyanate.

### Claim 18 (depends on 12)

The composition of claim 12, wherein the second cargo molecule is linked to any given number of cargo molecules in a polymeric fashion.

### Claim 19 (depends on 12)

The composition of claim 12, wherein the first cargo molecule is linked to the nucleic acid nanoparticle via reactions selected from the group consisting of CuAAC, SPAAC, RuAAC, IEDDA, SuFEx, SPANC, hydrazone/oxime ether formation, thiol-ene radical reaction, thiol-yne radical reaction, thiol-Michael addition reaction, thiol-isocyanate reaction, thiol-epoxide click reaction, nucleophilic ring opening reactions (spring-loaded reactions), traceless Staudinger ligation. These linkages may be formed by carrying out coupling reactions with any oligonucleotide or cargo molecule modified with a chemical moiety from the group consisting of, but not limited to, ADIBO-PEG4, N-[(1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl]-1,8-diamino-3,6-dioxaoctane, (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol, bromoacetamido-dPEG®4-amido-DBCO, bromoacetamido-dPEG®12-amido-DBCO, bromoacetamido-dPEG®24-amido-DBCO, dibenzocyclooctyne-acid, dibenzocyclooctyne-N-hydroxysuccinimidyl ester, dibenzocyclooctyne-PEG4-acid, dibenzocyclooctyne-PEG4-alcohol, dibenzocyclooctyne-PEG4-N-hydroxysuccinimidyl ester, (4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, (E)-cyclooct-4-enol, (E)-cyclooct-4-enyl 2,5-dioxo-1-pyrrolidinyl carbonate, 2,5-Dioxo-1-pyrrolidinyl 5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate, 5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoic acid, 5-norbornene-2-acetic acid succinimidyl ester, 5-norbornene-2-endo-acetic acid, methyltetrazine-NHS ester, methyltetrazine-PEG4-NHS ester, TCO PEG4 succinimidyl ester, TCO-amine, tetrazine-PEG5-NHS ester, alkyne-PEG5-acid, (R)-3-amino-5-hexynoic acid hydrochloride, (S)-3-amino-5-hexynoic acid hydrochloride, (S)-3-(boc-amino)-5-hexynoic acid, N-boc-4-pentyne-1-amine, boc-propargyl-Gly-OH, 3-ethynylaniline, 4-ethynylaniline, propargylamine hydrochloride, propargyl chloroformate, propargyl-N-hydroxysuccinimidyl ester, propargyl-PEG2-acid, 3-(4-azidophenyl)propionic acid, 3-azido-1-propanamine, 3-azido-1-propanol, 4-carboxybenzenesulfonazide, O-(2-aminoethyl)-O′-(2-azidoethyl)heptaethylene glycol, O-(2-aminoethyl)-O′-(2-azidoethyl)nonaethylene glycol, O-(2-aminoethyl)-O′-(2-azidoethyl)pentaethylene glycol, azido-dPEG®4(n)acid (where n could be 4, 8, 12, 24), azido-dPEG®(n)-amine (where n could be 7, 11, 23, 35), azido-dPEG®4(n) NHS ester (where n could be 4, 8, 12, 24), azido-dPEG®(n)-TFP ester (where n could be 4, 8, 12, 24, 36), 2-[2-(2-azidoethoxy)ethoxy]ethanol, O-(2-azidoethyl)-O-[2-(diglycolyl-amino)ethyl]heptaethylene glycol, O-(2-azidoethyl)heptaethylene glycol, O-(2-azidoethyl)-O′-methyl-triethylene glycol, O-(2-azidoethyl)-O′-methyl-undecaethylene glycol, 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-amine, 14-azido-3,6,9,12-tetraoxatetradecanoic acid, 11-azido-3,6,9-trioxaundecan-1-amine, bromoacetamido-dPEG®(n)azide (where n could be 3, 11, 23) and combinations thereof.

### Claim 20 (depends on 13)

The composition of claim 13, wherein each of at least two cargo molecules has a biological function.
